LT4176877T - Pacientų, sergančių fabri liga, širdies funkcijos gerinimo ir (arba) stabilizavimo būdai - Google Patents

Pacientų, sergančių fabri liga, širdies funkcijos gerinimo ir (arba) stabilizavimo būdai

Info

Publication number
LT4176877T
LT4176877T LTEP22194251.9T LT22194251T LT4176877T LT 4176877 T LT4176877 T LT 4176877T LT 22194251 T LT22194251 T LT 22194251T LT 4176877 T LT4176877 T LT 4176877T
Authority
LT
Lithuania
Prior art keywords
patients
improving
methods
heart function
stabilizing heart
Prior art date
Application number
LTEP22194251.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jeff Castelli
Jay Barth
Nina SKUBAN
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4176877(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of LT4176877T publication Critical patent/LT4176877T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP22194251.9T 2017-08-28 2018-08-28 Pacientų, sergančių fabri liga, širdies funkcijos gerinimo ir (arba) stabilizavimo būdai LT4176877T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28

Publications (1)

Publication Number Publication Date
LT4176877T true LT4176877T (lt) 2025-02-10

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP22194251.9T LT4176877T (lt) 2017-08-28 2018-08-28 Pacientų, sergančių fabri liga, širdies funkcijos gerinimo ir (arba) stabilizavimo būdai
LTEPPCT/US2018/048257T LT3675853T (lt) 2017-08-28 2018-08-28 Fabri liga sergančių pacientų širdies funkcijos stiprinimo ir (arba) stabilizavimo būdai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/048257T LT3675853T (lt) 2017-08-28 2018-08-28 Fabri liga sergančių pacientų širdies funkcijos stiprinimo ir (arba) stabilizavimo būdai

Country Status (26)

Country Link
US (1) US20200222377A1 (https=)
EP (3) EP4588476A1 (https=)
JP (3) JP7755929B2 (https=)
KR (2) KR102790184B1 (https=)
CN (1) CN111770753A (https=)
AR (1) AR112482A1 (https=)
AU (2) AU2018326364B2 (https=)
CA (1) CA3074450C (https=)
CL (1) CL2020000491A1 (https=)
DK (2) DK3675853T3 (https=)
EA (1) EA202090564A1 (https=)
ES (2) ES2931054T3 (https=)
FI (1) FI4176877T3 (https=)
HR (2) HRP20250064T1 (https=)
HU (2) HUE060287T2 (https=)
IL (3) IL272893B2 (https=)
LT (2) LT4176877T (https=)
MX (2) MX2020002229A (https=)
PL (2) PL4176877T3 (https=)
PT (2) PT4176877T (https=)
RS (2) RS66515B1 (https=)
SG (1) SG11202001707PA (https=)
SI (1) SI4176877T1 (https=)
SM (2) SMT202200459T1 (https=)
TW (1) TWI845479B (https=)
WO (1) WO2019046244A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CN111344912B (zh) 2017-08-28 2021-12-28 约翰·梅扎林瓜联合股份有限公司 同轴电缆连接器的天气防护壳体

Also Published As

Publication number Publication date
SMT202200459T1 (it) 2023-01-13
JP2025138638A (ja) 2025-09-25
MX2020002229A (es) 2020-07-20
TWI845479B (zh) 2024-06-21
RS63742B1 (sr) 2022-12-30
SG11202001707PA (en) 2020-03-30
PT3675853T (pt) 2022-11-28
HRP20250064T1 (hr) 2025-03-14
KR20250049561A (ko) 2025-04-11
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
EP3675853A1 (en) 2020-07-08
KR102790184B1 (ko) 2025-04-01
RS66515B1 (sr) 2025-03-31
IL272893B2 (en) 2024-07-01
IL310648A (en) 2024-04-01
SI4176877T1 (sl) 2025-03-31
AR112482A1 (es) 2019-10-30
EP3675853B1 (en) 2022-09-07
US20200222377A1 (en) 2020-07-16
AU2018326364B2 (en) 2024-08-29
IL272893A (en) 2020-04-30
CL2020000491A1 (es) 2020-09-11
IL272893B1 (en) 2024-03-01
DK4176877T3 (da) 2025-02-24
EP4176877B1 (en) 2024-12-04
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
LT3675853T (lt) 2022-12-12
EP4588476A1 (en) 2025-07-23
HUE060287T2 (hu) 2023-02-28
HRP20221366T1 (hr) 2023-01-06
TW201919619A (zh) 2019-06-01
ES2931054T3 (es) 2022-12-23
PL3675853T3 (pl) 2022-12-27
JP2020531550A (ja) 2020-11-05
AU2018326364A1 (en) 2020-04-09
DK3675853T3 (da) 2022-11-28
BR112020003974A2 (pt) 2020-09-01
ES3013820T3 (en) 2025-04-15
PT4176877T (pt) 2025-02-24
PL4176877T3 (pl) 2025-04-07
AU2024266945A1 (en) 2024-12-19
FI4176877T3 (fi) 2025-03-06
CN111770753A (zh) 2020-10-13
WO2019046244A1 (en) 2019-03-07
JP2023051998A (ja) 2023-04-11
CA3074450C (en) 2024-10-01
JP7755929B2 (ja) 2025-10-17
CA3074450A1 (en) 2019-03-07
KR20200044908A (ko) 2020-04-29
HUE070433T2 (hu) 2025-06-28
EP4176877A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
LT4176877T (lt) Pacientų, sergančių fabri liga, širdies funkcijos gerinimo ir (arba) stabilizavimo būdai
EP3313276A4 (en) HEART RATE VARIABILITY WITH SLEEP DETECTION
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
MA46284A (fr) Canule cardiaque
IL272300A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
DK3618884T3 (da) Blodpumpe med forstærket kateter
IL262591A (en) Methods for treating patients with familial hypercholesterolemia
DK3398626T3 (da) Intravaskulær blodpumpe med ballon
IL258459A (en) Therapeutic compositions for treatment of human immunodeficiency virus
EP3242605A4 (en) Angiogenic treatment of ischemic heart disease
DE112017002686T8 (de) Blutdruckmessmanschette und Blutdruckmessgerät
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
JP2016027901A5 (https=)
EP3777967A4 (en) HEART IMPLEMENTATION DEVICE AND STIMULATION SYSTEM
AU2014375637A1 (en) Formula of neuregulin preparation
IL269083A (en) Methods for preventing and treating heart disease
LT3749308T (lt) Klasikine fabri liga sergančių pacientų gydymas migalastatu
IL291725A (en) Methods and compositions for treating diabetic retinopathy
DE112018006114A5 (de) Kanüle, kanülensystem und blutpumpensystem
EP3668388C0 (en) CARDIAC REFERENCE UNIT AND BLOOD PRESSURE MONITORING DEVICE INCLUDING A CARDIAC REFERENCE UNIT
MA41782A (fr) Traitement de patients atteints de diabète de type 2
EP3681410A4 (en) HEART TREATMENT SYSTEM AND METHOD
EP3713608A4 (en) CATHETER RINSING SOLUTION INCLUDING SODIUM CITRATE AND BENZYL ALCOHOL
PT4324522T (pt) Métodos de tratamento de pacientes com fabry tendo insuficiência renal
EP3438986C0 (en) CLOSED-LOOP BLOOD GLUCOSE MONITORING SYSTEMS AND METHODS